Request Demo

Last update 10 Oct 2025

Metreleptin

Last update 10 Oct 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Hormone

Synonyms

Human recombinant methionyl leptin, Methionyl human leptin, Metreleptin (Genetical Recombination)

+ [10]

Target

LEPR

Action

agonists

Mechanism

LEPR agonists(Leptin receptor agonists)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Leptin DeficiencyLipodystrophy, Congenital GeneralizedLipodystrophy, Familial Partial+ [5]

Inactive Indication

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Fasting+ [5]

Originator Organization

The Rockefeller University

Active Organization

CHIESI Farmaceutici SpA

Amryt Pharma Holdings Ltd.Amryt Pharmaceuticals DAC

+ [3]

Inactive Organization

Amgen, Inc.

Amylin Pharmaceuticals, Inc.

AstraZeneca PLC

License Organization

Medison Pharma Ltd.

Amylin Pharmaceuticals, Inc.

AstraZeneca PLC

+ [6]

Drug Highest PhaseApproved

First Approval Date

Japan (25 Mar 2013),

Lipodystrophy

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 59859

Source: *****

Clinical Trials associated with Metreleptin

NCT06502990

/ RecruitingPhase 3

Open-label, Phase 3b Study to Evaluate Effectiveness, Safety and Pharmacokinetic Parameters of Metreleptin in Patients Under 6 Years of Age With Generalised Lipodystrophy and Associated Diabetes Mellitus and/or Hypertriglyceridaemia

This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia

Start Date23 May 2025

Sponsor / Collaborator

Amryt Pharma Holdings Ltd.

NCT06679270

/ RecruitingPhase 3

An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy

Start Date14 Oct 2024

Sponsor / Collaborator

Amryt Pharma Holdings Ltd.

NCT06484868

/ RecruitingPhase 4

A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy

This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy

Start Date08 Feb 2024

Sponsor / Collaborator

Amryt Pharma Holdings Ltd.

100 Clinical Results associated with Metreleptin

100 Translational Medicine associated with Metreleptin

100 Patents (Medical) associated with Metreleptin

336

Literatures (Medical) associated with Metreleptin

31 Dec 2025·SCANDINAVIAN CARDIOVASCULAR JOURNAL

Vasomotor and fibrinolytic effects of leptin in man

Article

Author: Robinson, Simon ; Newby, David E. ; Sandström, Thomas ; Blomberg, Anders ; Söderberg, Stefan ; Olsson, Tommy ; Eriksson, Marie ; Mills, Nicholas L. ; Gonzalez, Manuel

OBJECTIVES:

The adipocyte-derived hormone leptin has been associated with the pathogenesis of cardiovascular disease. The mechanisms underlying this association are unclear but may relate to effects on the vascular endothelium. Our aim was to explore the effects of leptin on endothelial vasomotor and fibrinolytic function in healthy volunteers and patients with coronary artery disease.

DESIGN:

The vascular effects of leptin were assessed infusing recombinant human leptin in healthy volunteers during measuring vasomotor response by venous occlusion plethysmography. Additionally, circulating levels of leptin were analysed in relation to endothelial dysfunction in patients with established coronary artery disease.

RESULTS:

In healthy male volunteers, intra-arterial infusion of recombinant human leptin (80, 800 and 8,000 ng/min; n = 10) did not affect basal forearm blood flow, plasma tissue plasminogen activator (tPA) or plasminogen activator inhibitor type 1 concentrations (all p > 0.05). However, during concomitant co-infusion with leptin (800 ng/min; n = 10), drug-induced vasodilatation was reduced (p = 0.001), and tPA activity increased (p = 0.002). In patients with coronary artery disease, those with the high plasma leptin levels had reduced drug-induced vasodilatation (p < 0.001), and increased net release of tPA antigen and activity (p < 0.001 and p = 0.03, respectively) compared to those with low levels. The study has been registered retrospectively at Clinical Trials with number NCT04374500.

CONCLUSION:

Intrabrachial leptin infusion did not affect the basal vascular tone, whereas acute and chronic hyperleptinemia was associated with blunted vasoreactivity in healthy volunteers, and in patients with coronary artery disease.

31 Dec 2025·Adipocyte

One-year metreleptin in Colombian sisters with congenital leptin deficiency

Article

Author: Restrepo, Carlos M ; Gonzalez, Adriana ; Celis-Regalado, Luis G ; Arango, Carlos ; Salinas-Osornio, Rocío A ; Laviada-Molina, Hugo A ; Bastarrachea, Raul A ; Licinio, Julio ; Huertas-Quintero, Jancy Andrea ; Yupanqui-Lozno, Hernan ; Hernandez-Escalante, Victor M ; Neri Morales, Constanza ; Nava-Gonzalez, Edna J ; Rodriguez-Ayala, Ernesto ; Yupanqui-Velazco, Maria E

We discovered two adult sisters in Colombia, lineally consanguineous, with severe obesity and undetectable serum leptin levels despite markedly elevated body fat. Their clinical profile included childhood-onset extreme weight gain, intense hunger, hyperphagia, hypogonadotropic hypogonadism, and family history of obesity. Direct sequencing of the LEP gene revealed a novel homozygous missense mutation in exon 3 (c.350G>T [p.C117F]). The presence of this mutation, undetectable leptin, and severe obesity confirmed a diagnosis of monogenic leptin deficiency. Here we describe the clinical outcomes of a 12-month treatment with recombinant human leptin (metreleptin). Metabolic and endocrine assessments were conducted before and after therapy. Metreleptin therapy significantly reduced BMI: from 59 to 38 kg/m² (OBX1, age 27) and 60 to 48 kg/m² (OBX2, age 24). Total body fat mass decreased, serum lipids normalized, and insulin sensitivity improved. Hypogonadotropic hypogonadism reversed, and menstruation resumed. Thus, metreleptin reversed the major metabolic and endocrine abnormalities associated with leptin deficiency in these sisters. Limitations include the small sample size, absence of a control group, and lack of anti-metreleptin antibody measurements. Nevertheless, our findings support that leptin replacement with metreleptin is currently the only effective hormonal treatment for this monogenic form of human obesity.

19 Aug 2025·JCEM case reports

Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2

Article

Author: Rodacki, Melanie ; Rodrigues Dantas, Joana ; Sued Leão, Isabella ; Galvão, Sarah ; Zajdenverg, Lenita

Abstract:

We describe our 8-year clinical experience with metreleptin in a Brazilian adult female patient with congenital generalized lipodystrophy type 2 (due to a mutation in the BSCL2 gene) and severe insulin resistance. The patient was initially treated with antidiabetic medications due to the unavailability of metreleptin. Metreleptin was initiated at age 20 years. Reductions from baseline for glycated hemoglobin (HbA1c) and triglycerides on metreleptin were sustained over a 5-year treatment period. The greatest reductions in HbA1c (from 10.8% [95 mmol/mol] to 6.0% [42 mmol/mol], −4.8%) and triglycerides (from 398 mg/dL [4.5 mmol/mL] to 104 mg/dL [1.2 mmol/L], −74%) occurred after 39 months, accompanied by a −95% decrease in total daily insulin usage (from 1600 to 88 IU/day). No significant adverse events occurred throughout metreleptin therapy. Metreleptin therapy was interrupted for 36 months due to limited access to the medication, during which time metabolic parameters deteriorated, returning to near-baseline levels. Thereafter, metreleptin was restarted. At the most recent clinic evaluation (3 months after resuming metreleptin), HbA1c, triglycerides, and liver enzyme levels reduced relative to the last measurements taken during treatment interruption. These findings provide support for the long-term and continuous use of metreleptin in patients with generalized lipodystrophy.

News (Medical) associated with Metreleptin

05 Feb 2025

·www.businesswire.com

Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) for its Congenital Generalized Lipodystrophy Program

SAN DIEGO--( BUSINESS WIRE )-- Entos ® Pharmaceuticals (Entos) , a clinical-stage genetic medicines company committed to using its Fusogenix™ PLV™ technology to develop cures and improve the lives of patients and their families, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M USD grant. The funds will support the completion of IND-enabling activities for the development of ENTLEP001, a durable genetic medicine for the treatment of congenital generalized lipodystrophy (CGL). CGL is a rare genetic disorder caused by mutations in the human leptin gene. People with CGL are leptin-deficient and cannot make adipose tissue. The disorder is associated with severe, hard-to-treat diabetes, hypertriglyceridemia, and potential complications affecting the liver and heart. ENTLEP001 is a systemically administered investigational gene therapy using the Fusogenix PLV platform to express unmodified human leptin in the body. The treatment is designed to be durable, redosable, and provide biologically relevant levels of native human leptin expression. Preclinical studies with ENTLEP001 using a leptin-deficient mouse model resulted in clinically relevant leptin expression, disease-modifying activity including normalization of glucose and insulin levels, and decreased weight gain and food intake. The Fusogenix PLV platform is a fusion-powered delivery system for genetic medicines that combines the best aspects of viral and non-viral approaches. Using a completely new mechanism for intracellular delivery of RNA, DNA and gene editing therapies, Fusogenix PLV is suitable for a wide range of best-in-class genetic medicines. Details regarding the platform’s safety, efficacy, and biodistribution in various animal models were published in Cell in September 2024. "Despite advancements in CGL treatment with FDA-approved metreleptin, there are still significant unmet needs," said Steve Chen, MD, CMO of Entos Pharmaceuticals. "Metreleptin requires daily subcutaneous injections and in some patients is associated with significant injection site adverse events. Although rare, there are reported cases of neutralizing anti-leptin antibody in patients receiving metreleptin. In contrast, ENTLEP001 is a genetic medicine that expresses native human leptin and may require dosing only once or twice a year, eliminating injection site reactions, simplifying patient compliance, and improving outcomes.” "This award from CIRM is an important validation for our lead program in CGL as we work to advance our second product into the clinic using the Fusogenix PLV platform,” said John Lewis, CEO of Entos Pharmaceuticals. “We deeply appreciate their support and recognition of the crucial need to address rare genetic disorders like congenital generalized lipodystrophy and the potential for novel genetic medicine approaches like the Fusogenix PLV to create life-changing treatments for patients and their families." About Congenital Generalized Lipodystrophy (CGL) Congenital generalized lipodystrophy (CGL), also known as Berardinelli-Seip syndrome, is a rare genetic disorder characterized by the near total loss of adipose tissue associated with extreme muscularity that is often present at birth or soon thereafter. CGL is associated with metabolic complications related to insulin resistance such as severe diabetes and hypertriglyceridemia. Diabetes associated with CGL is often very difficult to treat. Additional complications affecting the liver and heart can also occur. The symptoms and severity of CGL can vary greatly from one person to another. CGL is caused by mutations in the human leptin gene LEP . About Entos Pharmaceuticals Inc. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and re-dosable nucleic acid delivery technologies. Since its inception in 2016, Entos® has been dedicated to advancing next-generation genetic medicines using our proprietary Fusogenix™ PLV™ drug delivery system. The Fusogenix PLV platform is formulated with FAST proteins to enable the delivery of nucleic acid to target cells through direct fusion. Entos is pioneering the development of life-changing medicines for patients and has partnered with global companies, such as Eli Lilly, to accelerate and expand the impact of our platform. Entos Pharmaceuticals Inc. is headquartered in Edmonton, Canada, with its wholly owned U.S. and U.K. subsidiaries based in San Diego, California and London, United Kingdom, respectively. For more information, visit www.entospharma.com , or follow Entos on LinkedIn . About California Institute for Regenerative Medicine (CIRM) At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today’s most promising stem cell technologies. With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is the world’s largest institution dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go to www.cirm.ca.gov . Forward Looking Statements This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements contained in this press release include statements regarding Entos and its belief as to the mode of action and potential and benefits of the Fusogenix proteolipid vehicle platform and other statements related to anticipated developments in the Company’s business and technologies. In any forward-looking statement in which Entos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation, or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of Fusogenix as a nucleic acid delivery vehicle, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition. Investors should consult with the U.S. Securities Commission for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements except as required by applicable laws. Entos ® word mark and design logo, Fusogenix™ and PLV™ are registered trademarks of Entos Pharmaceuticals Inc. All other trademarks and registered trademarks are the property of their respective owners.

Gene Therapy

21 Nov 2024

·www.businesswire.com

Versant Ventures Unveils Pep2Tango Therapeutics Inc.

POTOMAC, Md.--( BUSINESS WIRE )--Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will support development of the company’s novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions. GLP-1-based therapies have proven efficacy in treating obesity and associated co-morbidities, but come with significant drawbacks. These include up to 40% of weight loss from muscle mass reduction, potentially leading to long-term side effects, especially in elderly patients. This limitation, in addition to tolerability issues, reduces the long-term utility of these agents. Pep2Tango’s lead drug candidates are engineered to overcome these drawbacks. They are unimolecular multi-receptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors. This unique combination of targets in one molecule is truly differentiated with key advantages compared with first-generation drugs on the market and therapies currently in development. Preclinical studies of Pep2Tango’s molecules have demonstrated superior weight loss versus tirzepatide, primarily through selective fat mass loss with preservation of muscle mass, improved blood lipid profiles, better glycemic control, and beneficial effects on the liver. The company’s programs were developed by a deeply experienced team led by President, CEO and Chairperson Cristina Rondinone, Ph.D., and CSO Soumitra Ghosh, Ph.D. Dr. Rondinone previously was president of Cellarity, and SVP and head of cardiovascular, renal and metabolic diseases at AstraZeneca plc. Prior to that, she held roles of increasing responsibility in cardio-metabolic disease research and development at MedImmune Inc., Roche and Abbott Laboratories, where she led the research and development of multiple molecules that moved to clinical trials including Rezdiffra ™ , dorzagliatin and bentracimab. Dr. Ghosh is a co-founder of multiple biotech companies and served as executive director for research at Amylin Pharmaceuticals Inc., where he was involved in development efforts culminating in the approvals of Byetta ® , Symlin ® , Bydureon ® and Myalept ® . Dr. Ghosh also served as president of the Peptide Therapeutics Foundation. “We are delighted that Versant is backing Pep2Tango as we advance our programs towards clinical development,” said Dr. Rondinone. “There is a critical need to develop safe and highly efficacious drug therapies for obesity that preserve muscle mass and Pep2Tango’s approach should positively impact the lives of patients.” “We are thrilled to partner with the seasoned team of experts at Pep2Tango,” said Carlo Rizzuto, Ph.D., managing director at Versant and a Pep2Tango board member. “We are convinced that the company’s tetra-receptor agonists have best-in-category potential with respect to magnitude and quality of weight loss, as well as improving metabolic and cardiovascular health, that could redefine obesity treatment.” Pep2Tango Therapeutics is focused on CMC development activities to scale up drug candidate manufacturing and on running IND-enabling studies for a rapid transition to first-in-human clinical studies. An IND submission is expected in 2025. About Pep2Tango Therapeutics Inc. Pep2Tango Therapeutics is a biotechnology company founded in 2021 by seasoned pharmaceutical executives with a long track record of successful drug development. The company’s vision is to develop next generation peptide drugs that target unmet medical needs, including for metabolic, endocrine, CNS and cardiovascular disorders. Pep2Tango’s novel drug development approach for obesity focuses on unimolecular peptides that target multiple receptors, allowing for superior weight loss efficacy, muscle mass preservation, improved tolerability, and streamlined development and manufacturability. The company is backed by Versant Ventures. About Versant Ventures Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com .

Drug ApprovalIPO

06 Feb 2024

·www.pharmaceutical-technology.com

Health Canada approves Chiesi’s MYALEPTA for lipodystrophy

The safety and efficacy of the asset in treating metabolic disorders linked to lipodystrophy syndromes were evaluated in an open-label, single-arm study. Credit: MikeSaran / shutterstock.com. Health Canada has approved Chiesi Group unit Chiesi Global Rare Diseases’ MYALEPTA (metreleptin for injection) to treat individuals with lipodystrophy, an ultra-rare condition. MYALEPTA is a replacement therapy adjunct to diet to address complications of leptin deficiency in patients with congenital or acquired forms of the disease. MYALEPTA can be used in adults and children aged two and above with confirmed congenital generalised lipodystrophy (Berardinelli-Seip syndrome) or acquired generalised lipodystrophy (Lawrence syndrome). It is also approved for patients aged 12 years and above with familial partial lipodystrophy (PL) or acquired PL (Barraquer-Simons syndrome). The treatment is intended for patients with metabolic disease who have not achieved adequate metabolic control with conventional treatments. MYALEPTA is originally developed by Amryt Pharma . Chiesi Group gained access to MYALEPTA through the acquisition of Amryt in April 2023. See Also: UK MHRA approves GSK’s momelotinib for myelofibrosis anaemia Germany’s Ministry of Health refutes accusations of worsening market conditions The safety and efficacy of the asset in treating metabolic disorders linked to lipodystrophy syndromes were evaluated in a long-term, open-label, single-arm study. The research was conducted under the supervision of the US National Institutes of Health. Weight decrease, hypoglycaemia and fatigue were the most commonly observed adverse drug reactions linked to the treatment. Chiesi Group Global Rare Diseases head Giacomo Chiesi stated: “We are very proud of the partnership that we have developed with Medison and applaud the team for their efforts to bring this innovative and important treatment to patients in Canada. “At the Chiesi Group, we are committed to creating a difference in the lives of patients with rare diseases and in collaboration with the Medison team, we have been able to achieve this for those living with lipodystrophy.”

Drug ApprovalAcquisition

100 Deals associated with Metreleptin

External Link

KEGG	Wiki	ATC	Drug Bank
D05014	Metreleptin	A16AA07	DB09046

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Leptin Deficiency	European Union	CHIESI Farmaceutici SpA	30 Jul 2018
Leptin Deficiency	Iceland	CHIESI Farmaceutici SpA	30 Jul 2018
Leptin Deficiency	Liechtenstein	CHIESI Farmaceutici SpA	30 Jul 2018
Leptin Deficiency	Norway	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Congenital Generalized	European Union	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Congenital Generalized	Iceland	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Congenital Generalized	Liechtenstein	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Congenital Generalized	Norway	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Familial Partial	European Union	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Familial Partial	Iceland	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Familial Partial	Liechtenstein	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Familial Partial	Norway	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Partial, Acquired	European Union	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Partial, Acquired	Iceland	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Partial, Acquired	Liechtenstein	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy, Partial, Acquired	Norway	CHIESI Farmaceutici SpA	30 Jul 2018
Lipodystrophy	Japan	Shionogi Pharma, Inc.	25 Mar 2013
Lipodystrophy	Japan	Chiesi Ltd.	25 Mar 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 3	Belgium	Amryt Pharma Holdings Ltd.	23 May 2025
Diabetes Mellitus	Phase 3	France	Amryt Pharma Holdings Ltd.	23 May 2025
Diabetes Mellitus	Phase 3	Germany	Amryt Pharma Holdings Ltd.	23 May 2025
Diabetes Mellitus	Phase 3	Italy	Amryt Pharma Holdings Ltd.	23 May 2025
Hypertriglyceridemia	Phase 3	Belgium	Amryt Pharma Holdings Ltd.	23 May 2025
Hypertriglyceridemia	Phase 3	France	Amryt Pharma Holdings Ltd.	23 May 2025
Hypertriglyceridemia	Phase 3	Germany	Amryt Pharma Holdings Ltd.	23 May 2025
Hypertriglyceridemia	Phase 3	Italy	Amryt Pharma Holdings Ltd.	23 May 2025
Lipomatosis, Multiple Symmetrical	Phase 2	United States	Amryt Pharma Holdings Ltd.	01 Aug 2023
Hypothalamic amenorrhoea	Phase 2	United States	Amgen, Inc.	01 Apr 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05351164 (CTgov)	Phase 2	Lipomatosis, Multiple Symmetrical	4	Metreleptin	thfpmxkpud(zbbogbxfcs) = jfgpwnyhmd qhwsyzcdlm (nsdfmaqjmm, 3.2) View more	-	12 Jun 2025
ESMO2022	Not Applicable	Extensive stage Small Cell Lung Cancer Maintenance	34	leptin (Insulin-resistant patients (IR pts))	dtfoxtypem(mhfsnavaky): HR = 0.07 (95% CI, 0.13 - 0.449), P-Value = 0.0043 View more	-	10 Sep 2022
ESMO2022	Not Applicable	Extensive stage Small Cell Lung Cancer Maintenance	34	leptin (Non-insulin-resistant patients (NIR pts))		-	10 Sep 2022
NCT00085982 (CTgov)	Phase 2	Insulin Resistance	11	Metreleptin	jitobxdmkj(zkprsgmeds) = jfifphsjzt mvconpxgnu (bagrhacruu, 1.921) View more	-	15 Dec 2021
NCT02654977 (CTgov)	Phase 2	Lipodystrophy, Familial Partial \| Nonalcoholic Steatohepatitis	11	Metreleptin	uhrrtvpqlt(qmgnahhhaq) = vbwdsxhsej uehprrnltc (zhajrprcyv, sjzgtrnjet - xsgrujqcin) View more	-	24 Nov 2020
NCT01679197 (OR17-02, ENDO2020)	Phase 2	Lipodystrophy leptin \| IGF-1 \| apo B ... View more	18	Metreleptin	hhjlaxhvnh(ovfqpnbuvp) = meusmpxxnx bedivombsu (pqouvrtqtd ) View more	-	08 May 2020
NCT01679197 (SUN-607, ENDO2020)	Phase 2	Lipodystrophy ferritin \| hepcidin \| iron ... View more	19	Metreleptin Therapy	drekyffncy(gmrrkraavp) = uqqwcaevzy hpccncbhsw (jnetxotgfl ) View more	Positive	08 May 2020
NCT01679197 (SUN-607, ENDO2020)	Phase 2	Lipodystrophy ferritin \| hepcidin \| iron ... View more	19	Placebo	uedpzkzvbh(mmceutpeqs) = tgyjfkdepk ackidzotwd (wvxqbgaivp )	Positive	08 May 2020
NCT00659828 (CTgov)	Phase 2	Metabolic Syndrome \| Diabetes Mellitus \| Obesity	1	Recombinant methionyl human leptin	rexxllqtkv = fclulhfxqy qbvebovizj (btiytnyqks, chcczvuyzi - fodvznuyhh) View more	-	13 Feb 2020
NCT00657605 (CTgov)	Phase 2	Metabolic Syndrome \| Diabetes Mellitus \| Obesity	3	Recombinant methionyl human leptin	mlraktnnqe = rkaeslctqd zfjewnmoep (voqlzxhxib, gpbmyvfozz - bxnrzlpqxt) View more	-	13 Feb 2020
NCT01778556 (CTgov)	Phase 2	Lipodystrophy	25	Metreleptin (Leptin Naive)	xkchyssjkg(hacmsbggok) = fbuqwqqhcw dsafqmmqui (rfgskamgva, 2.3) View more	-	13 Nov 2019
NCT01778556 (CTgov)	Phase 2	Lipodystrophy	25	Metreleptin (On-leptin)	xkchyssjkg(hacmsbggok) = kcxhrwmznc dsafqmmqui (rfgskamgva, 4.1) View more	-	13 Nov 2019
NCT00265980 (CTgov)	Not Applicable	Weight Loss \| Obesity	22	Leptin	vroxerdghe(wpjsedslge) = wlpefdyzfw fngslphghy (pxdkoaiayh, 500) View more	-	18 Sep 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis